The tariff threat come just a few days after the White House sent letters to major drugmakers demanding slashed prices for US ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Pfizer CEO says drugmakers ‘are all ready to roll up their sleeves and execute’ as president demands more direct-to-consumer ...

Investing in clinical-stage biotechnology always carries significant risks, and aTyr is no exception. The company reported a ...

Trump is pushing drug companies to lower their prices, but experts cast doubt on how effective this endeavor will prove.

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

US FDA accepts for priority review Bristol Myers Squibb’s sBLA for Breyanzi to treat adult patients with relapsed or refractory MZL: Princeton, New Jersey Wednesday, August 6, 2 ...

In 2017, Megan Wanzo was pursuing health care ethics, uncertain but hopeful that she was on the right path, when she attended ...

The FDA accepted a supplemental application for Breyanzi to treat adults with relapsed or refractory marginal zone lymphoma ...

Contineum Therapeutics has pumped the brakes on two projects, freeing up resources to go full speed ahead in its pursuit of Bristol Myers Squibb in idiopathic pulmonary fibrosis.

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting earnings this Thursday morning. Here’s what ...